The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Stoke Therapeutics Inc shares valued at $128,411 were sold by Allan Jonathan on Dec 08 ’25. At $32.28 per share, Allan Jonathan sold 3,978 shares. The insider’s holdings dropped to 11,831 shares worth approximately $0.37 million following the completion of this transaction.
Also, Kaye Edward M. MD sold 13,430 shares, netting a total of over 433,385 in proceeds. Following the sale of shares at $32.27 each, the insider now holds 49,124 shares.
Before that, EDWARD M KAYE had added 13,430 shares to its account. In a trade valued at $414,584, the Director bought Stoke Therapeutics Inc shares for $30.87 each.
Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in mid July. As of December 20, 2024, Chardan Capital Markets has initiated its “Buy” rating for STOK.
Analyzing STOK Stock Performance
On last trading session, Stoke Therapeutics Inc [NASDAQ: STOK] rose 1.28% to $30.97. The stock’s lowest price that day was $30.075, but it reached a high of $31.135 in the same session. During the last five days, there has been a drop of approximately -11.94%. Over the course of the year, Stoke Therapeutics Inc shares have jumped approximately 247.20%.
Is Stoke Therapeutics Inc subject to short interest?
Stocks of Stoke Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.16 million shares to 10.72 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 10.56 million shares. A jump of 1.52% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 12.29 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.29.
Which companies own the most shares of Stoke Therapeutics Inc (STOK)?
In terms of Stoke Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 36 in the next 12 months, up nearly 17.72% from the previous closing price of $30.58. Analysts anticipate Stoke Therapeutics Inc stock to reach 50 by 2026, with the lowest price target being 28. In spite of this, 5 analysts ranked Stoke Therapeutics Inc stock as Buy at the end of 2026.
